July 3, 2024 02:51 PM EDT
Pharma

Ex­perts want to make it eas­i­er to get RSV vac­cines. Did they make it hard­er in­stead?

Max Bayer

Pharma Reporter

Last week, ex­perts on the CDC’s pan­el that sets vac­cine rec­om­men­da­tions cre­at­ed new guid­ance for who should get RSV shots head­ing in­to the sec­ond-ever sea­son …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times